Supernus Pharmaceuticals, Inc.
↗Rockville, MD, USA
Supernus Pharmaceuticals is a specialty biopharmaceutical company dedicated to developing and commercializing innovative treatments for central nervous system (CNS) disorders. The company leverages proprietary drug delivery technologies to create differentiated formulations for conditions such as ADHD, epilepsy, Parkinson's disease, and postpartum depression.
Following a strategic shift to diversify its portfolio, Supernus has expanded through both internal R&D and significant acquisitions, including the 2025 integration of Sage Therapeutics. The company focuses on high-growth CNS assets and maintains a robust commercial presence in the United States, supported by a specialized sales force targeting neurologists and psychiatrists.
CLASSIFICATION
SIZE & FINANCIALS
Employees:501-1000
Revenue:$719M (2025)
Founded:2005
Ownership:public
Status:operating
STOCK
Exchange:NASDAQ
Ticker:SUPN
Market Cap:$2.84B
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Small molecule
Active Trials:132
Trial Phases:-
FDA Approvals:10
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:Sage Therapeutics
Key Partnerships:United Therapeutics (Orenitram development)
COMPETITION
Position:Challenger
Competitors:Takeda, Acadia Pharmaceuticals, Jazz Pharmaceuticals
LEADERSHIP
Key Executives:
Jack Khattar - President and CEO
Timothy Dec - CFO
LINKS
Website:supernus.com
LinkedIn:LinkedIn Profile
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Supernus Pharmaceuticals, Inc. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Supernus Pharmaceuticals, Inc.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.